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Sagar Lonial is to be heartily congratulated on having brought
together an impressive array of established leaders in the field
of multiple myeloma (MM) to produce a comprehensive review
of this difficult disease and its management.
The book is divided into seven sections dealing with all the
major areas relevant to MM. The first section addresses ‘Biological
considerations and multiple myeloma’. The chapter relating to the
‘Epidemiology of MM’ (A Langston and D Francis) is a thoughtful
summary of current understanding of this topic and discusses the
intriguing issue of familial predisposition to MM, which is, as yet,
unexplained, but clearly has significant importance to the
pathophysiology of MM. The chapter that focuses on the tumour
microenvironment (M Raab and K Anderson) nicely summarises
the current state of knowledge concerning the inter-dependency of
MM tumour cells and the bone marrow microenvironment. This is
a current paradigm, championed by Professor Anderson’s group at
the Dana-Farber that has underpinned the development of the
so-called ‘novel therapies’, which has led to the significant
advances in MM treatment. The chapter on cytogenetics
(E Braggio, M Sebag and R Fonseca) is a detailed and thorough
overview of the cytogenetic abnormalities found in MM and of
their prognostic significance.
The second section of the book addresses ‘conventional’
cytotoxic treatments. The chapters by J-L Harousseau and
A Palumbo are typically authoritative and logical overviews of
the function of autologous stem cell transplantation and therapies
for non-transplant eligible patients, respectively. A chapter by
S Ailawadhi and A Chanan-Khan discusses the function of
anthracyclines in MM and reminds us that ‘conventional’ drugs
still have activity in this disease and should not be discarded from
the anti-MM armamentarium.
The third section addresses the immune-based therapies in MM
as well as comprehensive reviews about immunotherapy and
antibody-based approaches, and the function of allogeneic
transplantation is discussed (F Wang and E Waller). This issue
remains, arguably, one of the most important in the treatment of
MM. The chapter summarises the current data and we are left in no
doubt that further work is required to define the role of this
treatment in MM.
Section four, in over 60 pages, comprises a ‘state of the art’
overview of the data concerning the ‘novel agents’: thalidomide,
lenalidomide and bortezomib. Each chapter is authored by
recognised experts in the field and describes the early development
and later definitive clinical trial data that has led to the
establishment of these agents into frontline MM care. Population-
based data have shown that coincident with the advent of the
‘novel agents’, there has been the single most important increment
in outcome for patients with MM. Clearly, the next questions will
involve issues concerning the most appropriate sequencing of
these drugs, the most effective combinations, the continuing role
for ASCT in the ‘novel agent era’ and the best selection of therapy
for specific groups of patients.
Section five addresses ‘Current and Future Targets’. This is
arguably the most stimulating section of the book and different
chapters discuss, among others, hsp90, PI3K/Akt, mTOR, FGFR3
and HDAC inhibitors. Each chapter has been written by experts
in the field and offer clear and insightful reviews of these
emerging potential targets for therapy. For example, the chapter
by C Mitsiades on hsp90 ranges from scientific rationale to early
phase clinical trials in the area. The authors offer the hope that
new-targeted therapies will be developed and describe the strong
rationale for combining these agents with pre-existing ones
(e.g. hsp90 inhibitors with bortezomib). Let us hope that these
scientifically designed combinations will further improve
outcomes for patients with MM.
Section six addresses the most important area of supportive
care in MM. The issues discussed include bone disease and its
treatment with kyphoplasy and vertebroplasty, anaemia, functional
imaging and renal impairment. The final section addresses ‘Other
Plasma Cell Disorders’. These chapters comprise authoritative
reviews on Waldenstrom’s Macroglobulinemia, AL Amyloidosis,
the mysterious POEMS syndrome and MGUS. Penned by
recognised experts in the field, these chapters represent an
excellent resource and reference.
Overall, the book is an outstanding resource for clinicians
working in the area of MM, which will have long-lasting value and
relevance.
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